1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Surprise! It’s A Phase III Failure

 
• By Jessica Merrill

When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.

CrackedEggs_1200x675

When Bristol-Myers Squibb Co. announced Aug. 5 that a key Phase III trial testing the checkpoint inhibitor Opdivo (nivolumab) in first-line lung cancer, CheckMate 026, missed the primary progression-free survival endpoint, the news hit the company like a ton of bricks.

Given Bristol’s leading position in cancer immunotherapy, its massive R&D investment and meticulous development of Opdivo and fellow checkpoint inhibitor...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.